NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
IPO Year:
Exchange: NASDAQ
Website: nanovibronix.com
10-Q - NanoVibronix, Inc. (0001326706) (Filer)
DEFA14A - NanoVibronix, Inc. (0001326706) (Filer)
DEF 14A - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
10-Q - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
10-Q - NanoVibronix, Inc. (0001326706) (Filer)
10-K/A - NanoVibronix, Inc. (0001326706) (Filer)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided an update on recent business developments. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "We have made substantial progress over the last several months with regards to expanding distribution, raising commercial awareness and pursuing reimbursements from regulatory authorities. Our products continue to deliver impressive results with high patient satisfaction and importantly, we believe are positioned to fill a void in the market. We are highly opti
Signs Term Sheet for a License and Supply Agreement for Distribution of UroShield NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave ("SAW") Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH ("APOGEPHA"), a German pharmaceutical company, which specializes in the development, marketing, sales and distribution of urology products and services. Pursuant to the term sheet, the Company and APOHEPHA intend to enter into a definitive agreement, pursuant to which, APOHEPHA will dist
NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a letter of intent with Medici Medical LTD ("Medici"), a leading distributor of medical products in the Israeli healthcare market, to explore the opportunities for distribution of the Company's UroShield device in Israel. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "Expanding distribution of our products with leading distributors is a key driver to accelerating market adoption of UroShield. Medici has established channels and is a l
NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the second quarter financials and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase stockholder value. We are focused on several areas tha
NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The "pilot" phase of the study is the first component of the broader study. As previously announced on November 28, 2023, the company signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial ("RCT") study of UroShield to further advance clinical evidence of the efficacy of UroShield. This link will take you to the company's previous press
NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments. To Our Stockholders: We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need and fill a void in the market, which has the potential to increase value for our stockholders. We are focused on several
NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC ("CB Medical") for the sale and distribution of the Company's UroShield. UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain and discomfort ass
Distribution Partner, Delta Medical, Awarded a Five-Year Federal Supply Schedule Contract for PainShield by Department of Veterans Affairs NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective May 1, 2024, the Company's PainShield product will be included in the U.S. Department of Veteran Affairs' ("VA") Federal Supply Schedule ("FSS"), a program that supports the healthcare acquisition needs of the VA and other government agencies. Delta Medical, LLC, a service-disabled veteran-owned small
1x1 Meetings on Thursday, May 2, 2024ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 9:30 AM (Pacific Time). Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. will be hosting the presentation and answering questions at the conclusion.To access the live presentation, please use the following information:Planet MicroCap Showcase: VEGAS 2024Date: Wednesday,
NanoVibronix, Inc., (NASDAQ:NAOV)("NanoVibronix"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase value for our stockholders. We ar
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on
Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr
MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana
NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a healthcare device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced that the Company's Annual Meeting of Stockholders was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2021. All of the resolutions submitted for stockholder approval were adopted, including: Election of the six director nominees Approval of the amendment to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock. Ratification of appointment of Marcum LLP as the company's independent re
NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh
NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The "pilot" phase of the study is the first component of the broader study.As previously announced on November 28, 2023, the company signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial ("RCT") study of UroShield to further advance clinical evidence of the efficacy of UroShield. This link will take you to the company's previous press rel
NanoVibronix (NASDAQ:NAOV) reported quarterly losses of $(0.23) per share. This is a 65.67 percent increase over losses of $(0.67) per share from the same period last year. The company reported $921.00 thousand in sales this quarter. This is a 160.17 percent increase over sales of $354.00 thousand the same period last year.
NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC ("CB Medical") for the sale and distribution of the Company's UroShield.UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain and discomfort associa
Gainers Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved upwards by 41.17% to $0.15. The company's market cap stands at $18.6 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 28.37% to $0.38. The market value of their outstanding shares is at $108.1 million. Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 19.56% to $1.47. The company's market cap stands at $6.8 million. Ardelyx (NASDAQ:ARDX) stock increased by 16.64% to $7.92. The company's market cap stands at $1.8 billion. As per the news, the Q1 earnings report came out ye
Shares of Apple Inc. (NASDAQ:AAPL) rose sharply in today's pre-market trading after the company reported better reported better-than-expected results for its second quarter. The company announced a $110-billion stock buyback program and a one-penny-per-share increase in its quarterly dividend. Apple shares jumped 5.9% to $183.24 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Vaxxinity, Inc. (NASDAQ:VAXX) gained 45.8% to $0.1519 in pre-market trading after falling 9% on Thursday. Vaxxinity recently announced its intention to voluntarily delist and deregister its Class A common stock. El Pollo Loco Holdings, Inc. (NASDAQ:LOCO) gained
Distribution Partner, Delta Medical, Awarded a Five-Year Federal Supply Schedule Contract for PainShield by Department of Veterans Affairs
Gainers Akanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwards by 25.17% to $0.92. The market value of their outstanding shares is at $2.5 million. Predictive Oncology (NASDAQ:POAI) shares increased by 23.4% to $1.74. The market value of their outstanding shares is at $7.0 million. Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 19.0% to $0.99. The company's market cap stands at $1.7 million. Emergent BioSolutions (NYSE:EBS) stock moved upwards by 18.08% to $2.22. The company's market cap stands at $116.3 million. As per the press r
We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase value for our stockholders. We are focused on several areas that we believe will have a substantial impact on our growth and product adoption. Many of those areas of focus have begun showing positive results, as reflected in our most recent quarterly financial results. Our products continue to deliver impressive results with high patient satisfaction, with no adverse events. We are investing in sales improvement and long-term opportunities
Efforts Focused on Adding Therapeutic Functionality and Reducing CostsNanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. ("Veranex") to assist with the development of the company's next generation UroShield and PainShield products.Under the terms of the agreement, Veranex will provide certain research and development services as related to PainShield and UroShield.Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, "Teaming up with Veranex pro